ERBB2 and breast carcinoma: The function of FASN in drug resistance has been shown in pancreatic cancer cells resistant to gemcitabine20 and luminal A breast cancer cells (MCF7) resistant to adriamycin, Her2-overexpressing breast cancer cell lines (SK-Br3) resistant to docetaxel13, and ovarian cancer cells resistant to Herceptin21.